Breaking News on Global Pharmaceutical Technology & Manufacturing

Delivery formulations

News headlines

Red light for blue oxy: US FDA rejects Rexista's anti-abuse traits

26-Sep-2017 - The US FDA has rejected Intellipharmaceutics’ oxycodone product Rexista, raising concerns about the efficacy of its anti-abuse measures. 

Anti-malaria drug casts light on cancer therapy

25-Sep-2017 - A treatment combining anti-malaria drug artemisinin and light-sensitive molecules could kill cancer cells and hinder tumour growth, say researchers.

In cold (and thin) blood: snake venom to reverse anticoagulant treatments

21-Sep-2017 - The use of snake venom protein-inspired candidate PseudoXa in patients taking anticoagulants, could combat severe bleeding in emergency surgery, says VarmX.

US FDA warns Korean & Chinese firms for cGMP violations

20-Sep-2017 - The US Food and Drug Administration (FDA) has issued warning letters to Korean company Firson Co. and Chinese firm Wuxi Medical Instrument Factory, citing sterilisation violations.

Roche Spanish plant becomes eighth solid dose site for Recipharm

20-Sep-2017 - Recipharm has acquired a Spanish manufacturing plant and signed a supply deal with former owner Roche for a range of solid dose products worth €35m a year.

Dry powder development: Vectura’s BI alternative backed by Pulmatrix

19-Sep-2017 - Vectura has advanced plans to develop a dry powder inhaler to treat patients with chronic obstructive pulmonary disease (COPD) for the US market.

Recipharm to make clinical trial cancer candidate for Kancera

18-Sep-2017 - Recipharm will make clinical trial capsules to support oncology candidate KAND567, a former AstraZeneca Fractalkine receptor inhibitor being developed by Kancera.


Single shot in 'tiny coffee cups’ could deliver multiple vaccines, MIT

18-Sep-2017 - 3-D microparticles which degrade at differing rates in the body could allow multiple doses of drugs or vaccines to be administered in a single injection, say MIT researchers.

BMS inks $105m deal to access Halozyme drug delivery tech

14-Sep-2017 - Bristol-Myers Squibb will also make up to $160m in milestone payments for each candidate developed using Halozyme Therapeutics’ large-volume biologics delivery platform.

German inspectors find problems at Dr Reddy's' Duvvada plant

11-Sep-2017 - German regulators have found problems as Dr Reddy’s’ drug formulations plant in Duvvada, Vishakapatnam.

Roche sells Italian formulations plant to CMO Delpharm

06-Sep-2017 - Delpharm has been contracted to make solid and liquid forms for Roche after buying the facility in Milan.

Oramed looking for commercialisation partner for oral insulin in US

06-Sep-2017 - Oramed is eying up commercial partnerships for its oral insulin candidate following a positive meeting with the US FDA to discuss an appropriate approval pathway.

News in brief

Navesta opens LKR1.4bn sterile drug plant in Sri Lanka

04-Sep-2017 - Navesta Pharmaceuticals had opened a sterile drug manufacturing facility in Horana, Sri Lanka.

Gilead aims to expand CAR-T manufacturing capabilities post-Kite acquisition

01-Sep-2017 - Gilead says it is committed to driving down costs of CAR-T manufacturing after agreeing to buy late-stage cell and gene therapy firm KitePharma for $11.9bn.

US FDA says Acorda can't file Inbrija NDA and asks for production data

29-Aug-2017 - The US FDA has refused to let Acorda Therapeutics Inc. file an NDA for Inbrija, its inhalable version of levodopa.

Catalent looking to parenteral dosage form capability for future expansion

29-Aug-2017 - Catalent says it will focus its M&A strategy to fill the injectables capability gap in its CDMO offering.

Being for the $11.9bn benefit of investors of Kite: Gilead jumps into CAR-T

28-Aug-2017 - Gilead will add a late-stage CAR T-cell candidate and a facility in California capable of treating 5,000 patients per year through the $11.9bn deal.

Lonza expands Swiss drug product site, adds 50 jobs

25-Aug-2017 - Lonza will feed demand for its drug quality testing and formulation capabilities through an expansion at its Drug Product Services site in Basel, Switzerland.

Hikma upping injectables capacity by as much as 500% by end of 2017

22-Aug-2017 - Hikma has ramped up capacity at manufacturing facilities in the US and Portugal manufacturing to meet the growing demand for its lyophilised and oncology products.

Aerie Pharma to use DSM polymers to develop eye drug delivery tech

16-Aug-2017 - Aerie Pharmaceuticals Inc will use a DSM polymer technology to develop an implant to deliver AR-13154, its wet AMD drug candidate.

Key Industry Events


Access all events listing

Our events, Shows & Conferences...

Product Innovation